GlassScriptPhysician profile
Megan E Stephan
NPI 1407234412
$3,186.66
in general payments reported to CMS, 2019-2025
31 companies · $1,962 in 2025
The $1,962 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $421 · 2023: $276 · 2024: $370 · 2025: $1,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440 · Travel and Lodging: $988 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.75 |
| Travel and Lodging | $987.81 |
| Education | $180.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,539.60 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $209.01 | 2021-2023 | Andexxa |
| Celgene Corporation | $180.88 | 2024-2025 | Reblozyl, Pomalyst |
| Jazz Pharmaceuticals INC. | $155.54 | 2022-2025 | |
| Axsome Therapeutics, INC. | $124.28 | 2025 | Sunosi |
| Novo Nordisk INC | $118.48 | 2022 | |
| Harmony Biosciences LLC | $106.95 | 2025 | |
| Incyte Corporation | $99.95 | 2024 | |
| Janssen Biotech, INC. | $81.00 | 2023 | Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $70.90 | 2025 | |
| Janssen Pharmaceuticals, INC | $66.06 | 2021 | |
| Genentech USA, INC. | $43.16 | 2024 | Tecentriq |
| Astellas Pharma US INC | $37.27 | 2024 | Padcev, Vyloy |
| Novartis Pharmaceuticals Corporation | $33.43 | 2023 | |
| Pfizer INC. | $33.38 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $33.03 | 2021-2023 | |
| Pharmacosmos Therapeutics INC. | $23.81 | 2024 | Cosela |
| Eisai INC. | $21.60 | 2025 | |
| Gilead Sciences, INC. | $19.95 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.57 | 2022 | |
| Shield Therapeutics INC | $19.41 | 2023 | Accrufer |
| Adaptive Biotechnologies Corporation | $18.60 | 2023 | Clonoseq |
| Blueprint Medicines Corporation | $17.68 | 2021 | |
| Baxter Healthcare | $17.25 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Lilly USA, LLC | $16.95 | 2025 | Zepbound |
| G1 Therapeutics, INC. | $14.24 | 2022 | |
| Genzyme Corporation | $14.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.89 | 2023 | Reblozyl |
| Seagen INC. | $13.28 | 2023 | Tukysa |
| Organon LLC | $12.39 | 2022 | |
| 3b Medical, INC. | $11.12 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Stephan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.